Pricing Log in Create free account

Bicycle Therapeutics PLC Sponsored ADR (BCYC) vs Entrada Therapeutics, Inc. (TRDA)

Bicycle Therapeutics PLC Sponsored ADR and Entrada Therapeutics, Inc. are both Biotechnology companies. Bicycle Therapeutics PLC Sponsored ADR and Entrada Therapeutics, Inc. are of similar size ($182.9M and $177.2M). Bicycle Therapeutics PLC Sponsored ADR grew revenue faster over the last twelve months: 217.4% against −94.1%. Bicycle Therapeutics PLC Sponsored ADR has the higher net margin (−311.1% vs −3,537.7%) and the lower return on invested capital (−64,747.5% vs −1,060.2%). Across the 16 metrics below, Bicycle Therapeutics PLC Sponsored ADR leads on 12 and Entrada Therapeutics, Inc. on 4.

Valuation

Metric BCYC TRDA Biotechnology median
P/E n/m n/m 8.42
P/S 4.11 43.79 10.01
P/B 0.49 0.88 2.21
Price to free cash flow n/m n/m 21.01
EV/EBITDA 1.16 0.10 0.61
EV/Sales (3.88) (3.80) 9.41
Earnings yield (75.83%) (81.48%) (31.85%)
Free cash flow yield (82.88%) (65.47%) (24.58%)

Profitability

Metric BCYC TRDA Biotechnology median
Gross margin 100.00% 100.00% 65.16%
Operating margin (343.60%) (3,767.07%) 0.00%
Net margin (311.11%) (3,537.73%) 0.00%
Free cash flow margin (340.29%) (2,867.07%) 0.00%
Return on equity (32.30%) (54.09%) (56.36%)
Return on assets (26.47%) (44.35%) (48.04%)
Return on invested capital (64,747.54%) (1,060.24%) 0.00%

Growth

Metric BCYC TRDA Biotechnology median
Revenue growth (TTM) 217.44% (94.10%) 6.02%
EPS growth (last fiscal year) (8.97%) (306.55%) 30.26%
Revenue growth, 5-year CAGR 47.52% — 9.41%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric BCYC TRDA Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 12.08 10.89 4.72
Net debt to EBITDA 2.61 1.88 0.96

Dividend

Metric BCYC TRDA Biotechnology median
Dividend yield — — 0.08%
Payout ratio — — —

Size

Metric BCYC TRDA Biotechnology median
Market cap 182.88m 177.16m 132.35m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack